Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMVP5YE)

Drug Name
Doxorubicin Drug Info
Synonyms
doxorubicin; 23214-92-8; Doxil; Doxorubicine; Adriablastin; Doxorubicinum; 14-Hydroxydaunomycin; 14-Hydroxydaunorubicine; Doxorubicina; Adriamycin semiquinone; Doxorubicinum [INN-Latin]; Doxorubicine [INN-French]; Doxorubicina [INN-Spanish]; Myocet; FI 106; Doxorubicin [USAN:INN:BAN]; CCRIS 739; NDC 38242-874; HSDB 3070; UNII-80168379AG; NCI-C01514; EINECS 245-495-6; CHEMBL53463; CHEBI:28748; 5,12-Naphthacenedione,; ADM; ADR; ThermoDox; Aerosolized Doxorubicin; Doxorubicin citrate; RDF Rubex; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; DM2; JT9100000; Adiblastine (hydrochloride salt); Adr iablatina (hydrochloride salt); Adriablastine (hydrochloride salt); Adriablatina (hydrochloride salt); Adriacin (hydrochloride salt); Adriamycin PFS (TN); Adriamycin PFS (hydrochloride salt); Adriamycin RDF (TN); Adriamycin RDF (hydrochloride salt); Adriblastina (TN); Adriblastina (hydrochloride salt); Adriblatina (hydrochloride salt); Caelyx (TN); Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DOX-SL; Doxorubicin hydrochloride (hydrochloride salt); Doxorubicin-hLL1; Doxorubicin-hLL1 conjugate; Farmablastina (hydrochloride salt); Hydroxydaunomycin hydrochlor ide (hydrochloride salt); Hydroxydaunomycin hydrochloride (hydrochloride salt); Hydroxydaunorubicin hydrochloride (hydrochloride salt); Myocet (TN); Rubex (TN); Rubex (hydrochloride salt); TLC D-99; Doxorubicin (USAN/INN); Doxorubicin-P4/D10; Doxorubicin-P4/D10 conjugate; Cantide + adriamycin
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Approved [1] , [2]
Hepatocellular carcinoma 2C12.02 Phase 3 [3]
Breast cancer 2C60-2C65 Phase 2 [4]
Tumour 2A00-2F9Z Investigative [5]
Therapeutic Class
Anticancer Agents
Cross-matching ID
PubChem CID
31703
ChEBI ID
CHEBI:28748
CAS Number
CAS 23214-92-8
TTD Drug ID
DMVP5YE
VARIDT Drug ID
DR00301
INTEDE Drug ID
DR0546

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
DTP
DME
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Investigative Drug(s)
Discontinued Drug(s)
Download the Complete Related Drug List
Drug(s) Metabolized By Cytochrome P450 3A4 (CYP3A4)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Premature labour JB00 Approved [29]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [30]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [31]
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [32]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [33]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [34]
Zidovudine DM4KI7O Human immunodeficiency virus infection 1C62 Approved [35]
Prasterone DM67VKL Chronic obstructive pulmonary disease CA22 Approved [29]
Verapamil DMA7PEW Hypertension BA00-BA04 Approved [36]
Diclofenac DMPIHLS Osteoarthritis FA00-FA05 Approved [37]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 2D6 (CYP2D6)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Premature labour JB00 Approved [38]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [39]
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [32]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [36]
Quinine DMSWYF5 Malaria 1F40-1F45 Approved [40]
Propofol DMB4OLE Anaesthesia 9A78.6 Approved [41]
Dopamine DMPGUCF Parkinson disease 8A00.0 Approved [42]
Nicotine DMWX5CO Nicotine dependence 6C4A.2 Approved [43]
Propranolol DM79NTF Migraine 8A80 Approved [44]
Amitriptyline DMK7F9S Depression 6A70-6A7Z Approved [45]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Cytochrome P450 3A5 (CYP3A5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Progesterone DMUY35B Premature labour JB00 Approved [46]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [47]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [48]
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [49]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [50]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [51]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [52]
Verapamil DMA7PEW Hypertension BA00-BA04 Approved [53]
Sorafenib DMS8IFC Hepatocellular carcinoma 2C12.02 Approved [48]
Estrone DM5T6US Menopausal and postmenopausal disorder GA30 Approved [54]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Metabolized By Xanthine dehydrogenase/oxidase (XDH)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Xanthine DMFBOQ7 Apnea MD11.0 Phase 1 [55]
Drug(s) Metabolized By NADPH-cytochrome P450 reductase (CPR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Daunorubicin DMQUSBT Acute myeloid leukaemia 2A60 Approved [56]
Nitrofurantoin DM7PQIK Urinary tract infection GC08 Approved [57]
Tacrolimus DMZ7XNQ Organ transplant rejection NE84 Approved [58]
Benzphetamine DMIJATC Obesity 5B81 Approved [59]
Nilutamide DMFN07X Prostate cancer 2C82.0 Approved [60]
Menadiol sodium diphosphate DMP9N85 Coagulation defect 3B10.0 Approved [61]
Amrubicin DM6SGUB Small-cell lung cancer 2C25.Y Phase 3 [62]
Nitrobenzodiazepine DM254EW Discovery agent N.A. Investigative [63]
⏷ Show the Full List of 8 Drug(s)
Drug(s) Metabolized By Quinone reductase 1 (NQO1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [64]
Oxaliplatin DMQNWRD Colorectal cancer 2B91.Z Approved [64]
Carboplatin DMG281S Ovarian cancer 2C73 Approved [64]
Beta-lapachone DMMI84K Solid tumour/cancer 2A00-2F9Z Phase 2 [65]
CB1954 DMVP4YK Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [66]
Nitrobenzanthrone DMN6L70 Discovery agent N.A. Investigative [67]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Aldo-keto reductase 1A1 (AKR1A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Ethanol DMDRQZU Chronic pain MG30 Approved [68]
NADH DM5NM6E Parkinson disease 8A00.0 Approved [69]
2,3-dihydroxypropanal DMOWNB4 Discovery agent N.A. Investigative [70]
Nitrobenzaldehyde DM4UHB5 Discovery agent N.A. Investigative [70]
D-glucuronate DM1YBTC Discovery agent N.A. Investigative [70]
BRN-0471734 DMZMWVX Discovery agent N.A. Investigative [70]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Aldo-keto reductase 1C3 (AKR1C3)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fenofibric acid DMGO2MC Cardiovascular disease BA00-BE2Z Approved [71]
Androsterone DMITJAK N. A. N. A. Phase 3 [72]
Trastuzumab Emtansine DMU1LXS HER2-positive breast cancer 2C60-2C65 Phase 2 [73]
4-oxo-nonenal DMPX1J9 Discovery agent N.A. Investigative [74]
Acenaphthenol DMT3QYZ Discovery agent N.A. Investigative [72]
Indan-1-ol DMMLQZJ Discovery agent N.A. Investigative [72]
⏷ Show the Full List of 6 Drug(s)
Drug(s) Metabolized By Succinic semialdehyde reductase (AKR7A2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Vilaprisan DME7VZD Endometriosis GA10 Phase 2 [75]
Drug(s) Metabolized By Methionine synthase reductase (MTRR)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [76]
Menadione DMSJDTY Vitamin K deficiency 5B59 Approved [25]
Dichloroindophenol DMAEI51 Discovery agent N.A. Investigative [25]
Ferricyanide DM1TH08 Discovery agent N.A. Investigative [25]
Drug(s) Transported By Multidrug resistance-associated protein 1 (ABCC1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [77]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [78]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [79]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [80]
Verapamil DMA7PEW Hypertension BA00-BA04 Approved [81]
Irinotecan DMP6SC2 Colorectal cancer 2B91.Z Approved [82]
Glutathione DMAHMT9 Human immunodeficiency virus infection 1C62 Approved [83]
Phenytoin DMNOKBV Epilepsy 8A60-8A68 Approved [84]
Daunorubicin DMQUSBT Acute myeloid leukaemia 2A60 Approved [85]
Docetaxel DMDI269 Solid tumour/cancer 2A00-2F9Z Approved [81]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Multidrug resistance-associated protein 2 (ABCC2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [86]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [87]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [88]
Dinoprostone DMTYOPD Medical abortion JA00.1Z Approved [89]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [90]
Acetaminophen DMUIE76 Pain MG30-MG3Z Approved [91]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [92]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [93]
Oxaliplatin DMQNWRD Colorectal cancer 2B91.Z Approved [94]
Ampicillin DMHWE7P Bacterial infection 1A00-1C4Z Approved [95]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By P-glycoprotein 1 (ABCB1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Amoxicillin DMUYNEI Bacterial infection 1A00-1C4Z Approved [81]
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [95]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [96]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [95]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [95]
Progesterone DMUY35B Premature labour JB00 Approved [97]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [95]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [98]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [99]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [100]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Breast cancer resistance protein (ABCG2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Methotrexate DM2TEOL leukaemia 2A60-2B33 Approved [101]
Folic acid DMEMBJC Folate-deficiency anemia 3A02.Y Approved [102]
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [103]
Cisplatin DMRHGI9 Solid tumour/cancer 2A00-2F9Z Approved [104]
Progesterone DMUY35B Premature labour JB00 Approved [105]
Tamoxifen DMLB0EZ Breast cancer 2C60-2C65 Approved [106]
Estradiol DMUNTE3 Breast cancer 2C60-2C65 Approved [105]
Sulfasalazine DMICA9H Irritable bowel syndrome DD91.0 Approved [107]
Imatinib DM7RJXL Acute lymphoblastic leukaemia 2A85 Approved [108]
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [109]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By ATP-binding cassette sub-family B member 5 (ABCB5)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Brigatinib DM7W94S Anaplastic large cell lymphoma 2A90.A Approved [110]
Fostamatinib DM6AUHV Immune thrombocytopenic purpura 3B64.13 Approved [111]
Drug(s) Transported By Monocarboxylate transporter 1 (SLC16A1)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Atorvastatin DMF28YC Cardiovascular disease BA00-BE2Z Approved [112]
Salicyclic acid DM2F8XZ Seborrhoeic dermatitis EA81 Approved [112]
Gamma hydroxybutyric acid DMGBKVD Narcolepsy 7A20 Approved [113]
Pyruvic acid DM7Q41G Malnutrition 5B50-5B71 Approved [114]
Gabapentin enacarbil DMJY2TM Alcohol dependence 6C40.2 Phase 2 [115]
Pyroglutamic acid DMROZUA Discovery agent N.A. Investigative [116]
Butanoic acid DMTAJP7 Discovery agent N.A. Investigative [115]
Hydroxyacetic acid DMQFBH6 Discovery agent N.A. Investigative [117]
Biotin DMKMCE1 Discovery agent N.A. Investigative [118]
Milchsaure DM462BT Metabolic acidosis 5C73 Investigative [119]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Transported By Fly-like putative transporter 2 (SLC22A16)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Levacecarnine HCL DMJBOCR Cognitive impairment 6D71 Approved [120]
Drug(s) Targeting TERT messenger RNA (TERT mRNA)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Fluorouracil DMUM7HZ Solid tumour/cancer 2A00-2F9Z Approved [5]
2,7-Bis(acetamido)anthraquinone DM2EPM4 Discovery agent N.A. Investigative [121]
2,7-Bis(cyclohexanecarbonamido)anthraquinone DMTPZ8D Discovery agent N.A. Investigative [121]
2,7-Bis[2-(isopropylamino)acetamido]anthraquinone DMRQGWX Discovery agent N.A. Investigative [121]
NSC-745884 DM8W0J3 Discovery agent N.A. Investigative [122]
2,7-Bis[3-(piperidino)propionamido]anthraquinone DMET693 Discovery agent N.A. Investigative [121]
2,7-Bis(cyclopropanecarbonamido)anthraquinone DMY3V2B Discovery agent N.A. Investigative [121]
2,7-Bis(phenylacetamido)anthraquinone DMEVIBT Discovery agent N.A. Investigative [121]
NSC-745887 DMG9BWY Discovery agent N.A. Investigative [122]
2,7-Bis[2-(butylamino)acetamido]anthraquinone DM3GTV0 Discovery agent N.A. Investigative [121]
⏷ Show the Full List of 10 Drug(s)
Drug(s) Targeting DNA topoisomerase II (TOP2)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Etoposide DMNH3PG Solid tumour/cancer 2A00-2F9Z Approved [123]
Teniposide DMLW57T Acute lymphoblastic leukaemia 2A85 Approved [6]
Mitoxantrone DMM39BF Solid tumour/cancer 2A00-2F9Z Approved [124]
Idarubicin DMM0XGL Acute myeloid leukaemia 2A60 Approved [6]
Epirubicin DMPDW6T Solid tumour/cancer 2A00-2F9Z Approved [6]
Lomefloxacin DMVRH9C Bacterial infection 1A00-1C4Z Approved [125]
Dexrazoxane DMD7X1O Breast cancer 2C60-2C65 Approved [6]
Podofilox DMT2EJP Condyloma 1A95 Approved [126]
Enoxacin DMYTE6L Urinary tract infection GC08 Approved [127]
Amsacrine DMZKYIV Acute lymphoblastic leukaemia 2A85 Approved [128]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas
Download the Complete Interaction Atlas for Visualization in Cytoscape

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [6]
TERT messenger RNA (TERT mRNA) TTQY2EJ TERT_HUMAN Not Available [5]

Drug Transporter (DTP)
DTP Name DTP ID UniProt ID MOA REF
ATP-binding cassette sub-family B member 8 (ABCB8) DT0KQND ABCB8_HUMAN Substrate [7]
ATP-binding cassette sub-family B member 5 (ABCB5) DTKVEXO ABCB5_HUMAN Substrate [8]
Fly-like putative transporter 2 (SLC22A16) DTPATLS S22AG_HUMAN Substrate [9]
Monocarboxylate transporter 1 (SLC16A1) DT342ZG MOT1_HUMAN Substrate [10]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [11]
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [12]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [13]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [14]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [15]

Drug-Metabolizing Enzyme (DME)
DME Name DME ID UniProt ID MOA REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Substrate [16]
Cytochrome P450 2D6 (CYP2D6) DECB0K3 CP2D6_HUMAN Substrate [17]
Cytochrome P450 3A5 (CYP3A5) DEIBDNY CP3A5_HUMAN Substrate [18]
Quinone reductase 1 (NQO1) DENP5RY NQO1_HUMAN Substrate [19]
Nitric oxide synthase inducible (NOS2) DE3C1JY NOS2_HUMAN Substrate [20]
Nitric oxide synthase endothelial (NOS3) DE708H2 NOS3_HUMAN Substrate [20]
NADPH-cytochrome P450 reductase (CPR) Main DME DE3N2FM NCPR_HUMAN Substrate [21]
Aldo-keto reductase 1C3 (AKR1C3) DEGQTXO AK1C3_HUMAN Substrate [22]
Nitric oxide synthase brain (NOS1) DEYEK78 NOS1_HUMAN Substrate [20]
Aldo-keto reductase 1A1 (AKR1A1) DED2FW3 AK1A1_HUMAN Substrate [23]
Xanthine dehydrogenase/oxidase (XDH) Main DME DECG04O XDH_HUMAN Substrate [24]
NADH-ubiquinone oxidoreductase 30 kDa (NDUFS3) DE741FI NDUS3_HUMAN Substrate [19]
NADH-ubiquinone oxidoreductase 49 kDa (NDUFS2) DEKX5CD NDUS2_HUMAN Substrate [19]
Methionine synthase reductase (MTRR) DE6NIY9 MTRR_HUMAN Substrate [25]
Succinic semialdehyde reductase (AKR7A2) DE4G629 ARK72_HUMAN Substrate [26]
NADH-ubiquinone oxidoreductase 20 kDa (NDUFS7) DEIW03B NDUS7_HUMAN Substrate [19]
NADH dehydrogenase (nuoE) DEAMEF2 J9VB37_9ACTN Substrate [27]
Molybdopterin-dependent enzyme (molD) DEME01W A0A327UAE0_9ACTN Substrate [28]
Molybdopterin-dependent enzyme (molD) DEYSOD0 A0A327SQQ7_9ACTN Substrate [28]
Molybdopterin-dependent enzyme (molD) DE1QMDG A0A327U7N1_9ACTN Substrate [28]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7069).
2 Natural products as sources of new drugs over the last 25 years. J Nat Prod. 2007 Mar;70(3):461-77.
3 ClinicalTrials.gov (NCT02112656) Study of ThermoDox With Standardized Radiofrequency Ablation (RFA) for Treatment of Hepatocellular Carcinoma (HCC) (OPTIMA). U.S. National Institutes of Health.
4 Antitumor activity of liposome-encapsulated doxorubicin in advanced breast cancer: phase II study. J Natl Cancer Inst. 1990 Nov 7;82(21):1706-10.
5 Design and development of antisense drugs. Expert Opin. Drug Discov. 2008 3(10):1189-1207.
6 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
7 ABCB8 mediates doxorubicin resistance in melanoma cells by protecting the mitochondrial genome. Mol Cancer Res. 2009 Jan;7(1):79-87.
8 ABCB5-mediated doxorubicin transport and chemoresistance in human malignant melanoma. Cancer Res. 2005 May 15;65(10):4320-33.
9 Influence of pharmacogenetics on response and toxicity in breast cancer patients treated with doxorubicin and cyclophosphamide. Br J Cancer. 2010 Mar 16;102(6):1003-9.
10 Circadian rhythms in gene expression: Relationship to physiology, disease, drug disposition and drug action. Adv Drug Deliv Rev. 2010 Jul 31;62(9-10):904-17.
11 Involvement of the drug transporters p glycoprotein and multidrug resistance-associated protein Mrp2 in telithromycin transport. Antimicrob Agents Chemother. 2006 Jan;50(1):80-7.
12 The role of bioreductive activation of doxorubicin in cytotoxic activity against leukaemia HL60-sensitive cell line and its multidrug-resistant sublines. Br J Cancer. 2005 Jul 11;93(1):89-97.
13 Doxorubicin transport by RALBP1 and ABCG2 in lung and breast cancer. Int J Oncol. 2007 Mar;30(3):717-25.
14 MDR1 (ABCB1) G1199A (Ser400Asn) polymorphism alters transepithelial permeability and sensitivity to anticancer agents. Cancer Chemother Pharmacol. 2009 Jun;64(1):183-8.
15 Fingerprint-based in silico models for the prediction of P-glycoprotein substrates and inhibitors. Bioorg Med Chem. 2012 Sep 15;20(18):5388-95.
16 Expression levels and activation of a PXR variant are directly related to drug resistance in osteosarcoma cell lines. Cancer. 2007 Mar 1;109(5):957-65.
17 Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes. Cancer Chemother Pharmacol. 1993;32(6):491-5.
18 Drug related genetic polymorphisms affecting adverse reactions to methotrexate, vinblastine, doxorubicin and cisplatin in patients with urothelial cancer. J Urol. 2008 Dec;180(6):2389-95.
19 Differential ability of cytostatics from anthraquinone group to generate free radicals in three enzymatic systems: NADH dehydrogenase, NADPH cytochrome P450 reductase, and xanthine oxidase. Oncol Res. 2003;13(5):245-52.
20 The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage. FASEB J. 2004 Apr;18(6):664-75.
21 Kinetics of anthracycline antibiotic free radical formation and reductive glycosidase activity. Arch Biochem Biophys. 1983 May;223(1):68-75.
22 Inactivation of the anticancer drugs doxorubicin and oracin by aldo-keto reductase (AKR) 1C3. Toxicol Lett. 2008 Sep;181(1):1-6.
23 Carbonyl reductase 1 is a predominant doxorubicin reductase in the human liver. Drug Metab Dispos. 2008 Oct;36(10):2113-20.
24 Xanthine oxidoreductase in drug metabolism: beyond a role as a detoxifying enzyme. Curr Med Chem. 2016;23(35):4027-4036.
25 Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry. 2002 Nov 12;41(45):13378-85.
26 Naturally occurring variants of human aldo-keto reductases with reduced in vitro metabolism of daunorubicin and doxorubicin. J Pharmacol Exp Ther. 2010 Dec;335(3):533-45.
27 Bacterial inactivation of the anticancer drug doxorubicin. Chem Biol. 2012 Oct 26;19(10):1255-64.
28 Transformation of the anticancer drug doxorubicin in the human gut microbiome. ACS Infect Dis. 2018 Jan 12;4(1):68-76.
29 Contribution of human hepatic cytochrome P450 isoforms to regioselective hydroxylation of steroid hormones. Xenobiotica. 1998 Jun;28(6):539-47.
30 Comprehensive evaluation of tamoxifen sequential biotransformation by the human cytochrome P450 system in vitro: prominent roles for CYP3A and CYP2D6. J Pharmacol Exp Ther. 2004 Sep;310(3):1062-75.
31 Isoform-specific regulation of cytochromes P450 expression by estradiol and progesterone. Drug Metab Dispos. 2013 Feb;41(2):263-9.
32 Metabolic interactions between acetaminophen (paracetamol) and two flavonoids, luteolin and quercetin, through in-vitro inhibition studies. J Pharm Pharmacol. 2017 Dec;69(12):1762-1772.
33 Potent mechanism-based inhibition of CYP3A4 by imatinib explains its liability to interact with CYP3A4 substrates. Br J Pharmacol. 2012 Apr;165(8):2787-98.
34 Effects of morin on the pharmacokinetics of etoposide in rats. Biopharm Drug Dispos. 2007 Apr;28(3):151-6.
35 The metabolism of zidovudine by human liver microsomes in vitro: formation of 3'-amino-3'-deoxythymidine. Biochem Pharmacol. 1994 Jul 19;48(2):267-76.
36 Substrates, inducers, inhibitors and structure-activity relationships of human Cytochrome P450 2C9 and implications in drug development. Curr Med Chem. 2009;16(27):3480-675.
37 Cytochrome P450 3A4-mediated interaction of diclofenac and quinidine. Drug Metab Dispos. 2000 Sep;28(9):1043-50.
38 Effect of genetic polymorphism on the metabolism of endogenous neuroactive substances, progesterone and p-tyramine, catalyzed by CYP2D6. Brain Res Mol Brain Res. 2004 Oct 22;129(1-2):117-23.
39 CYP2D6 polymorphisms and tamoxifen metabolism: clinical relevance. Curr Oncol Rep. 2010 Jan;12(1):7-15.
40 Inhibition of cytochrome P450 2D6: structure-activity studies using a series of quinidine and quinine analogues. Chem Res Toxicol. 2003 Apr;16(4):450-9.
41 Effects of propofol on human hepatic microsomal cytochrome P450 activities. Xenobiotica. 1998 Sep;28(9):845-53.
42 Pharmacogenetics of schizophrenia. Am J Med Genet. 2000 Spring;97(1):98-106.
43 Roles of CYP2A6 and CYP2B6 in nicotine C-oxidation by human liver microsomes. Arch Toxicol. 1999 Mar;73(2):65-70.
44 Structure-activity relationship for human cytochrome P450 substrates and inhibitors. Drug Metab Rev. 2002 Feb-May;34(1-2):69-82.
45 Bioactivation of the tricyclic antidepressant amitriptyline and its metabolite nortriptyline to arene oxide intermediates in human liver microsomes and recombinant P450s. Chem Biol Interact. 2008 May 9;173(1):59-67.
46 Human prostate CYP3A5: identification of a unique 5'-untranslated sequence and characterization of purified recombinant protein. Biochem Biophys Res Commun. 1999 Jul 14;260(3):676-81.
47 Polymorphisms in cytochrome P4503A5 (CYP3A5) may be associated with race and tumor characteristics, but not metabolism and side effects of tamoxifen in breast cancer patients. Cancer Lett. 2005 Jan 10;217(1):61-72.
48 Drug Interactions Flockhart Table
49 Induction of hepatic CYP2E1 by a subtoxic dose of acetaminophen in rats: increase in dichloromethane metabolism and carboxyhemoglobin elevation. Drug Metab Dispos. 2007 Oct;35(10):1754-8.
50 Urinary 6 beta-hydroxycortisol excretion in rheumatoid arthritis. Br J Rheumatol. 1997 Jan;36(1):54-8.
51 Clinical pharmacokinetics of imatinib. Clin Pharmacokinet. 2005;44(9):879-94.
52 Kinetics and regulation of cytochrome P450-mediated etoposide metabolism. Drug Metab Dispos. 2004 Sep;32(9):993-1000.
53 Differential mechanism-based inhibition of CYP3A4 and CYP3A5 by verapamil. Drug Metab Dispos. 2005 May;33(5):664-71.
54 16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5. Carcinogenesis. 1998 May;19(5):867-72.
55 Molecular characterization and taurine regulation of two novel CDOs (CDO1 and CDO2) from Carassius auratus. Comp Biochem Physiol B Biochem Mol Biol. 2019 Sep;235:54-61.
56 Lack of mechanism-based inactivation of rat hepatic microsomal cytochromes P450 by doxorubicin. Can J Physiol Pharmacol. 1999 Aug;77(8):589-97.
57 Role of cytochrome P450 reductase in nitrofurantoin-induced redox cycling and cytotoxicity. Free Radic Biol Med. 2008 Mar 15;44(6):1169-79.
58 Polymorphisms in cytochrome P450 oxidoreductase and its effect on drug metabolism and efficacy. Pharmacogenet Genomics. 2017 Sep;27(9):337-346.
59 On the mechanism of the inactivation of the major phenobarbital-inducible isozyme of rat liver cytochrome P-450 by chloramphenicol. J Biol Chem. 1985 Jul 15;260(14):8397-403.
60 Generation of free radicals during the reductive metabolism of nilutamide by lung microsomes: possible role in the development of lung lesions in patients treated with this anti-androgen. Biochem Pharmacol. 1992 Feb 4;43(3):654-7.
61 Creatinine sulfate/esculoside/hesperidin methyl chalcone/menadiol sodium phosphate/tranexamic acid actions.
62 Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride. Xenobiotica. 2005 Dec;35(12):1121-33.
63 Flavin-containing reductase: new perspective on the detoxification of nitrobenzodiazepine. Expert Opin Drug Metab Toxicol. 2010 Aug;6(8):967-81.
64 PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med. 2018 Jul;10(4):e1417. (ID: PA150642262)
65 Beta-lapachone, a modulator of NAD metabolism, prevents health declines in aged mice. PLoS One. 2012;7(10):e47122.
66 Gene Therapy of the Central Nervous System. Charter 22 - Prodrug-Activation Gene Therapy. 2006, Pages 291-301
67 Dose-dependent response to 3-nitrobenzanthrone exposure in human urothelial cancer cells. Chem Res Toxicol. 2017 Oct 16;30(10):1855-1864.
68 Functional assessment of human alcohol dehydrogenase family in ethanol metabolism: significance of first-pass metabolism. Alcohol Clin Exp Res. 2006 Jul;30(7):1132-42.
69 Conformational changes and catalysis by alcohol dehydrogenase. Arch Biochem Biophys. 2010 Jan 1;493(1):3-12.
70 The C-terminal loop of aldehyde reductase determines the substrate and inhibitor specificity. Biochemistry. 1996 Nov 12;35(45):14276-80.
71 In vitro metabolism of fenofibric acid by carbonyl reducing enzymes. Chem Biol Interact. 2016 Oct 25;258:153-8.
72 Expression and characterization of four recombinant human dihydrodiol dehydrogenase isoforms: oxidation of trans-7, 8-dihydroxy-7,8-dihydrobenzo[a]pyrene to the activated o-quinone metabolite benzo[a]pyrene-7,8-dione. Biochemistry. 1998 May 12;37(19):6781-90.
73 The role of carbonyl reducing enzymes in oxcarbazepine in vitro metabolism in man. Chem Biol Interact. 2014 Sep 5;220:241-7.
74 Instability of C154Y variant of aldo-keto reductase 1C3. Chem Biol Interact. 2017 Oct 1;276:194-202.
75 Characterization of the pharmacokinetics of vilaprisan: bioavailability, excretion, biotransformation, and drug-drug interaction potential. Clin Pharmacokinet. 2018 Aug;57(8):1001-1015.
76 Polymorphisms in genes involved in folate metabolism as maternal risk factors for Down syndrome in China. J Zhejiang Univ Sci B. 2008 Feb;9(2):93-9.
77 Transport of methotrexate (MTX) and folates by multidrug resistance protein (MRP) 3 and MRP1: effect of polyglutamylation on MTX transport. Cancer Res. 2001 Oct 1;61(19):7225-32.
78 Folate concentration dependent transport activity of the Multidrug Resistance Protein 1 (ABCC1). Biochem Pharmacol. 2004 Apr 15;67(8):1541-8.
79 Hammerhead ribozyme against gamma-glutamylcysteine synthetase sensitizes human colonic cancer cells to cisplatin by down-regulating both the glutathione synthesis and the expression of multidrug resistance proteins. Cancer Gene Ther. 2001 Oct;8(10):803-14.
80 Multidrug resistance-associated protein-1 functional activity in Calu-3 cells. J Pharmacol Exp Ther. 2001 Sep;298(3):1199-205.
81 Human intestinal transporter database: QSAR modeling and virtual profiling of drug uptake, efflux and interactions. Pharm Res. 2013 Apr;30(4):996-1007.
82 ATP-Dependent efflux of CPT-11 and SN-38 by the multidrug resistance protein (MRP) and its inhibition by PAK-104P. Mol Pharmacol. 1999 May;55(5):921-8.
83 Structural determinants of substrate specificity differences between human multidrug resistance protein (MRP) 1 (ABCC1) and MRP3 (ABCC3). Drug Metab Dispos. 2008 Dec;36(12):2571-81.
84 Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology. 2010 Jun;58(7):1019-32.
85 Vinblastine and sulfinpyrazone export by the multidrug resistance protein MRP2 is associated with glutathione export. Br J Cancer. 2000 Aug;83(3):375-83.
86 Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models. Drug Metab Dispos. 2011 Nov;39(11):2155-61.
87 Mammalian multidrug-resistance proteins (MRPs). Essays Biochem. 2011 Sep 7;50(1):179-207.
88 Enhancing chemosensitivity in oral squamous cell carcinoma by lentivirus vector-mediated RNA interference targeting EGFR and MRP2. Oncol Lett. 2016 Sep;12(3):2107-2114.
89 Multidrug resistance associated protein 2 mediates transport of prostaglandin E2. Liver Int. 2006 Apr;26(3):362-8.
90 Lentivirus-mediated RNAi silencing targeting ABCC2 increasing the sensitivity of a human nasopharyngeal carcinoma cell line against cisplatin. J Transl Med. 2008 Oct 4;6:55.
91 Effect of acetaminophen on expression and activity of rat liver multidrug resistance-associated protein 2 and P-glycoprotein. Biochem Pharmacol. 2004 Aug 15;68(4):791-8.
92 Small intestinal efflux mediated by MRP2 and BCRP shifts sulfasalazine intestinal permeability from high to low, enabling its colonic targeting. Am J Physiol Gastrointest Liver Physiol. 2009 Aug;297(2):G371-7.
93 Delineating the contribution of secretory transporters in the efflux of etoposide using Madin-Darby canine kidney (MDCK) cells overexpressing P-glycoprotein (Pgp), multidrug resistance-associated protein (MRP1), and canalicular multispecific organic anion transporter (cMOAT). Drug Metab Dispos. 2002 Apr;30(4):457-63.
94 Multidrug Resistance-Associated Protein 2 (MRP2) Mediated Transport of Oxaliplatin-Derived Platinum in Membrane Vesicles. PLoS One. 2015 Jul 1;10(7):e0130727.
95 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
96 Folate transporter expression decreases in the human placenta throughout pregnancy and in pre-eclampsia. Pregnancy Hypertens. 2012 Apr;2(2):123-31.
97 Comparative studies on in vitro methods for evaluating in vivo function of MDR1 P-glycoprotein. Pharm Res. 2001 Dec;18(12):1660-8.
98 Antiestrogens and steroid hormones: substrates of the human P-glycoprotein. Biochem Pharmacol. 1994 Jul 19;48(2):287-92.
99 Association of genetic polymorphisms in the influx transporter SLCO1B3 and the efflux transporter ABCB1 with imatinib pharmacokinetics in patients with chronic myeloid leukemia. Ther Drug Monit. 2011 Apr;33(2):244-50.
100 Efflux ratio cannot assess P-glycoprotein-mediated attenuation of absorptive transport: asymmetric effect of P-glycoprotein on absorptive and secretory transport across Caco-2 cell monolayers. Pharm Res. 2003 Aug;20(8):1200-9.
101 Wild-type breast cancer resistance protein (BCRP/ABCG2) is a methotrexate polyglutamate transporter. Cancer Res. 2003 Sep 1;63(17):5538-43.
102 The effect of low pH on breast cancer resistance protein (ABCG2)-mediated transport of methotrexate, 7-hydroxymethotrexate, methotrexate diglutamate, folic acid, mitoxantrone, topotecan, and resveratrol in in vitro drug transport models. Mol Pharmacol. 2007 Jan;71(1):240-9.
103 Role of BCRP as a biomarker for predicting resistance to 5-fluorouracil in breast cancer. Cancer Chemother Pharmacol. 2009 May;63(6):1103-10.
104 Inhibiting the function of ABCB1 and ABCG2 by the EGFR tyrosine kinase inhibitor AG1478. Biochem Pharmacol. 2009 Mar 1;77(5):781-93.
105 Sterol transport by the human breast cancer resistance protein (ABCG2) expressed in Lactococcus lactis. J Biol Chem. 2003 Jun 6;278(23):20645-51.
106 The phytoestrogen genistein enhances multidrug resistance in breast cancer cell lines by translational regulation of ABC transporters. Cancer Lett. 2016 Jun 28;376(1):165-72.
107 Curcumin inhibits the activity of ABCG2/BCRP1, a multidrug resistance-linked ABC drug transporter in mice. Pharm Res. 2009 Feb;26(2):480-7.
108 Imatinib mesylate (STI571) is a substrate for the breast cancer resistance protein (BCRP)/ABCG2 drug pump. Blood. 2004 Nov 1;104(9):2940-2.
109 Characterization of 3-methoxy flavones for their interaction with ABCG2 as suggested by ATPase activity. Biochim Biophys Acta. 2014 Nov;1838(11):2929-38.
110 NDA/BLA Multidisciplinary Review and Evaluation of ALUNBRIG (brigatinib) From FDA.
111 DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Res. 2018 Jan 4;46(D1):D1074-D1082. (ID: DB12010)
112 H+-coupled nutrient, micronutrient and drug transporters in the mammalian small intestine. Exp Physiol. 2007 Jul;92(4):603-19.
113 Flavonoids modulate monocarboxylate transporter-1-mediated transport of gamma-hydroxybutyrate in vitro and in vivo. Drug Metab Dispos. 2007 Feb;35(2):201-8.
114 AR-C155858 is a potent inhibitor of monocarboxylate transporters MCT1 and MCT2 that binds to an intracellular site involving transmembrane helices 7-10. Biochem J. 2010 Jan 15;425(3):523-30.
115 Overview of the proton-coupled MCT (SLC16A) family of transporters: characterization, function and role in the transport of the drug of abuse gamma-hydroxybutyric acid. AAPS J. 2008 Jun;10(2):311-21.
116 Interaction of atorvastatin with the human glial transporter SLC16A1. Eur J Pharmacol. 2016 Oct 5;788:248-254.
117 Cidofovir peptide conjugates as prodrugs. Journal of Organometallic Chemistry, 2005, 690(10):2673-2678.
118 Biotin. Biofactors. 2009 Jan-Feb;35(1):36-46.
119 Distribution of monocarboxylate transporters MCT1-MCT8 in rat tissues and human skeletal muscle. Appl Physiol Nutr Metab. 2006 Feb;31(1):31-9.
120 The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem. 2010 Feb 26;285(9):6275-84.
121 Synthesis, human telomerase inhibition and anti-proliferative studies of a series of 2,7-bis-substituted amido-anthraquinone derivatives. Bioorg Med Chem. 2008 Jul 15;16(14):6976-86.
122 Synthesis, cytotoxicity and human telomerase inhibition activities of a series of 1,2-heteroannelated anthraquinones and anthra[1,2-d]imidazole-6,1... Bioorg Med Chem. 2009 Nov 1;17(21):7418-28.
123 Etoposide, topoisomerase II and cancer.Curr Med Chem Anticancer Agents.2005 Jul;5(4):363-72.
124 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
125 Inhibition of human topoisomerase IIalpha by fluoroquinolones and ultraviolet A irradiation. Toxicol Sci. 2002 Sep;69(1):16-22.
126 Antitumor properties of podophyllotoxin and related compounds. Curr Pharm Des. 2000 Dec;6(18):1811-39.
127 Clinical pharmacokinetics of the newer antibacterial 4-quinolones. Clin Pharmacokinet. 1988 Feb;14(2):96-121.
128 Design of two etoposide-amsacrine conjugates: topoisomerase II and tubuline polymerization inhibition and relation to cytotoxicity. Anticancer Drug Des. 2000 Dec;15(6):413-21.